7 years of historical data (2018–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Immunome, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $623M | $212M | $27M | $150M | $98M | — | — |
| Enterprise Value | $1.9B | $484M | $115M | $7M | $101M | $59M | — | — |
| P/E Ratio → | -4.37 | — | — | — | — | — | — | — |
| P/S Ratio | 221.74 | 68.88 | 15.15 | — | — | — | — | — |
| P/B Ratio | 7.08 | 3.44 | 1.77 | 1.61 | 3.10 | 2.37 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 53.56 | 8.23 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Immunome, Inc. earns an operating margin of -3382.4%. Operating margins have compressed from -781.4% to -3382.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -194.6% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -3382.4% | -3382.4% | -781.4% | — | — | — | — | — |
| Net Profit Margin | -3240.4% | -3240.4% | -761.9% | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -194.6% | -194.6% | -156.5% | -113.8% | -55.2% | -624.2% | — | — |
| ROA | -150.7% | -150.7% | -123.8% | -90.0% | -48.2% | -71.9% | -221.9% | -176.4% |
| ROIC | -700.3% | -700.3% | -843.7% | — | -2580.6% | — | — | — |
| ROCE | -195.6% | -195.6% | -152.7% | -113.7% | -56.2% | -54.6% | -329.4% | -268.2% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $143M exceeds total debt of $5M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.01 | 0.02 | 0.01 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.76 | -0.81 | -1.20 | -1.02 | -0.95 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -7380.20 | -2520.40 | -322.66 | -97.62 | -54.91 |
Net cash position: cash ($143M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
Immunome, Inc.'s current ratio of 4.08x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.09x to 4.08x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.08 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 | 1.88 | 1.35 |
| Quick Ratio | 4.08 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 | 1.88 | 1.35 |
| Cash Ratio | 4.00 | 4.00 | 6.33 | 2.77 | 5.06 | 13.09 | 1.53 | 1.03 |
| Asset Turnover | — | 0.04 | 0.09 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 7.53 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Immunome, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $59M | $20M | $12M | $12M | $10M | $6M | $1M |
Compare IMNM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| IMNMYou | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| TECX | $439M | -6.0 | — | — | — | — | -206.6% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 7 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how IMNM stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonImmunome, Inc.'s current P/E ratio is -4.4x. This places it at the 50th percentile of its historical range.
Immunome, Inc.'s return on equity (ROE) is -194.6%. The historical average is -130.0%.
Based on historical data, Immunome, Inc. is trading at a P/E of -4.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Immunome, Inc. has 100.0% gross margin and -3382.4% operating margin.